When was BioGenomics founded?

BioGenomics was founded in 2002 and raised its 1st funding round 20 years after it was founded.

Where is BioGenomics located?

BioGenomics is headquartered in Thane, India. It is registered at 1-A,Valliamal Road, Opp. Seventh Day Adventist School, Vepery, CHENNAI , Unclassified TN 600007.

Who is the current CEO of BioGenomics?

Sanjay Sonar of BioGenomics. They have also founded 1 company.

Which legal entities is BioGenomics associated with?

BioGenomics is associated with Biogenomics Limited and 1 other.

How many employees does BioGenomics have?

As of Mar 31, 2025, BioGenomics has 126 employees, reflecting a 1% year-over-year growth in headcount.

Is BioGenomics a funded company?

BioGenomics is a funded company, having raised a total of $24.6M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jan 11, 2022.

How much is BioGenomics worth?

The latest valuation of BioGenomics is ₹***** as of May 22, 2022.

When was the latest funding round of BioGenomics?

BioGenomics' latest funding was a $***** Seed round on Jul 03, 2022, with participation from 1 investor.

What is the annual revenue of BioGenomics?

Annual revenue of BioGenomics is ₹10.7Cr as on Mar 31, 2023.

Where does BioGenomics rank among its competitors?

BioGenomics ranks 909th amongst 3434 active competitors, of which 1186 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Moderna, which secured $590M in Jan, 2025.

Who are the top competitors of BioGenomics?

BioGenomics' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Moderna secured the most recent funding round in January, 2025.

BioGenomics - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of recombinant DNA-based biosimilars, recombinant proteins, and enzymes. It offers recombinant DNA based technology platformfor biosimilars development, cell-culture reagents and enzymes. These reagents are ideal replacements for animal-derived proteins and enzymes so that the entire production process can be made completely animal origin free.

Website: biogenomics.co.in
Email ID: *****@biogenomics.co.in, *****@biogenomics.co.in
Phone Number: +91 **********
Registered Address: 1-A,Valliamal Road, Opp. Seventh Day Adventist School, Vepery, CHENNAI , Unclassified TN 600007

Key Metrics

Founded Year

2002

Location

Thane, India

Stage

Seed

Total Funding

$24.6M in 2 rounds

Latest Funding Round

Seed, Jul 03, 2022, $*****

Post Money Valuation

₹***** as on May 22, 2022

Investors

Oman Investment Authority & 1 more

Ranked

909^th among 3434 active competitors

Annual Revenue

₹10.7Cr as on Mar 31, 2023

Employee Count

126 as on Mar 31, 2025

Similar Companies

Jazz Pharmaceuticals & 3243 more

View BioGenomics' full profile

BioGenomics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
BIOGENOMICS LIMITED CIN: U24234PY2002PLC009158 , India, Active	Apr 24, 2002	$2.53M (As on Mar 31, 2025)	172 (As on Sep 30, 2024)
Biogenomics Limited CIN: U24234TN2002PLC048821 , India, Active	Apr 23, 2002	$1.33M (As on Mar 31, 2023)	141 (As on Aug 01, 2025)

BioGenomics has raised a total funding of $24.6M over 2 rounds. Its first funding round was on Jan 11, 2022. Its latest funding round was a Seed round on Jul 03, 2022 for $*****. 1 investor participated in its latest round. BioGenomics has 2 institutional investors.

Here is the list of recent funding rounds of BioGenomics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 03, 2022	1967604	Seed	9076064	6496586	1862681	1067899
Jan 11, 2022	1835187	Seed	8434748	6058397	Eagle Asia Holding	8879292

Access funding benchmarks and valuations. Sign up today!

View details of BioGenomics's funding rounds and investors

The founders of BioGenomics is Sanjay Sonar. Sanjay Sonar is the CEO of BioGenomics.

Here are the details of BioGenomics' key team members:

Sanjay Sonar: Co-Founder & Owner & President & CEO of BioGenomics.
Contact Info: 1 email address and 1 phone number

BioGenomics' Board of Directors

BioGenomics's board has 7 active members. Archana Krishnan is part of team and Imran Jamiluddin Shaikh, Rajesh Shashikant Dalal, Ranjan Mohan Mogre, Vijayanand Ramchandra Bhate, Ammar Abdullah Hamad Al Ali and Namit Rustagi are independent board members.

Here is the list of BioGenomics' board of directors:

Name	Type	Representing	Status	Duration
Archana Krishnan	Team	-	Current	20y 3m
Imran Jamiluddin Shaikh	Independent board member	-	Current	1y 8m
xwxvevr	Independent board member	-	Current	2y 1m
prnbzjc	Independent board member	-	Current	5y 6m
hkdj{kr	Independent board member	-	Current	5y 4m
vmfnhtm	Independent board member	-	Current	5y 6m
irixhan	Independent board member	-	Current	6y 7m

View details of BioGenomics's Founder profiles and Board Members

BioGenomics' employee count trend

BioGenomics has 126 employees as of Mar 25. The total employee count is 1.0% more than what it was in Mar 24. Here is BioGenomics's employee count trend over the years:

Uncover BioGenomics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of BioGenomics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of BioGenomics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating human disease conditions	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
4th	Senti Biosciences 2016, San Francisco (United States), Public	Developer of cell-based therapies for cancer treatment	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
5th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
7th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 18 others	72/100
10th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, Astrazeneca & 31 others	71/100
909th	BioGenomics 2002, Thane (India), Seed	Developer of recombinant DNA-based biosimilars, recombinant proteins, and enzymes	$24.6M	Oman Investment Authority & 1 others	44/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on BioGenomics's competitors? Click here to see the top ones

Founders own 3.14%, Parent Entities (largest shareholder) own 52.35%, Enterprises own 38.46% and Other Investors own 6.05%. The net worth of BioGenomics's founders is INR 14.9Cr as of May 22, 2022.

Shareholders Name	Post Round Holding %	Net worth	Cumulative Investment	Realised Returns	Unrealised Returns	Return Multiple
Founder	3.14%	14.9Cr	549	889	871	259
Sanjay Sonar	1	7	7	7	2	2
Parent Entity	52.35%	248Cr	8365108	6026398	4302362	8313662
Enterprise	38.46%	183Cr	2286771	1166757	3985554	4387596
Other Investors	6.05%	28.7Cr	281345	458417	584389	279047
Total	100.00%	475Cr	4934388	8906653	6263723	1411391